Clinical Roundup Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC November 14, 2025Vol.51 No.42
Clinical Roundup Alliance launches trial to study exercise in cancer patients November 14, 2025Vol.51 No.42
Clinical Roundup Researchers discover gene that could help improve treatment decisions in childhood leukemia November 14, 2025Vol.51 No.42
Drugs & Targets Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors November 14, 2025Vol.51 No.42
Regulatory News CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”Cancer advocates express concern about comments that signal trouble for accelerated approval November 07, 2025Vol.51 No.41By Claire Marie Porter and Paul Goldberg
Guest Editorial How George Tidmarsh crossed the FDA-industry Rubicon November 07, 2025Vol.51 No.41By Mikkael A. Sekeres
Guest Editorial How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care November 07, 2025Vol.51 No.41By Kathy Davy
Cancer Policy HHS (again) postpones USPSTF meeting November 07, 2025Vol.51 No.41By Claire Marie Porter
Cancer Policy Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients November 07, 2025Vol.51 No.41By Jacquelyn Cobb
